CRYO CELL INTERNATIONAL INC Segments Disclosure
NOTE 5 – SEGMENT REPORTING
The Company is organized in three reportable segments:
The Company’s chief operating decision maker (“CODM”) is its , who review financial information for the purposes of making operating decisions, assessing financial performance and allocating resources.
The CODM uses net income as reported on the consolidated statements of operations to assess segment performance and determine how to allocate resources. Total assets as presented on the consolidated balance sheets is used to
measure segment assets. The CODM reviews significant expense categories that materially align with those presented in the consolidated statements of operations.
The following table shows, by segment: net revenue, cost of sales, operating profit, depreciation and amortization, interest expense, and assets for the years ended November 30, 2025 and November 30, 2024:
|
|
For the years ended November 30, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
Net revenue: |
|
|
|
|
|
|
||
Umbilical cord blood and cord tissue stem cell service |
|
$ |
31,382,704 |
|
|
$ |
31,551,550 |
|
PrepaCyte CB |
|
|
54,104 |
|
|
|
67,884 |
|
Public cord blood banking |
|
|
129,513 |
|
|
|
366,672 |
|
Total net revenue |
|
$ |
31,566,321 |
|
|
$ |
31,986,106 |
|
Cost of sales: |
|
|
|
|
|
|
||
Umbilical cord blood and cord tissue stem cell service |
|
$ |
6,639,186 |
|
|
$ |
6,889,882 |
|
PrepaCyte CB |
|
|
23,280 |
|
|
|
45,082 |
|
Public cord blood banking |
|
|
714,182 |
|
|
|
1,012,788 |
|
Total cost of sales |
|
$ |
7,376,648 |
|
|
$ |
7,947,752 |
|
Operating profit: |
|
|
|
|
|
|
||
Umbilical cord blood and cord tissue stem cell service |
|
$ |
5,411,691 |
|
|
$ |
4,131,796 |
|
PrepaCyte CB |
|
|
14,206 |
|
|
|
(4,976 |
) |
Public cord blood banking |
|
|
(4,943,503 |
) |
|
|
(646,536 |
) |
Total operating profit |
|
$ |
482,394 |
|
|
$ |
3,480,284 |
|
Depreciation and amortization: |
|
|
|
|
|
|
||
Umbilical cord blood and cord tissue stem cell service |
|
$ |
734,856 |
|
|
$ |
455,324 |
|
PrepaCyte CB |
|
|
16,618 |
|
|
|
27,778 |
|
Public cord blood banking |
|
|
— |
|
|
|
420 |
|
Total depreciation and amortization |
|
$ |
751,474 |
|
|
$ |
483,522 |
|
Interest expense: |
|
|
|
|
|
|
||
Umbilical cord blood and cord tissue stem cell service |
|
$ |
2,066,256 |
|
|
$ |
1,864,684 |
|
PrepaCyte CB |
|
|
— |
|
|
|
— |
|
Public cord blood banking |
|
|
— |
|
|
|
— |
|
Total interest expense |
|
$ |
2,066,256 |
|
|
$ |
1,864,684 |
|
The following table shows the assets by segment as of November 30, 2025 and November 30, 2024:
|
|
As of |
|
|
As of |
|
||
|
|
November 30, 2025 |
|
|
November 30, 2024 |
|
||
Assets: |
|
|
|
|
|
|
||
Umbilical cord blood and cord tissue stem cell |
|
$ |
60,788,322 |
|
|
$ |
59,259,451 |
|
PrepaCyte CB |
|
|
135,379 |
|
|
|
138,169 |
|
Public cord blood banking |
|
|
804,813 |
|
|
|
5,280,013 |
|
Total assets |
|
$ |
61,728,514 |
|
|
$ |
64,677,633 |
|
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 27, 2026 | Showing above |
| 2024 | Feb 28, 2025 | |
| 2023 | Feb 28, 2024 | |
| 2022 | Feb 28, 2023 | |
| 2021 | Feb 22, 2022 | |
| 2020 | Mar 1, 2021 | |
| 2019 | Feb 28, 2020 | |
| 2018 | Feb 28, 2019 | |
| 2017 | Feb 28, 2018 | |
| 2016 | Feb 28, 2017 | |
| 2015 | Feb 29, 2016 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.